Bioseek Share Discussion Threads

[and then] 31/3/2011 17:01

Ok, so here's a potential swing trade set-up, i want to keep an eye on...







The overhead resistance goes back to mid 2008, the rising wedge that's been forming is coming to an end, that's a reversal pattern. Combine the two and i think 14300 (also being a round number giving solid res/support in the past) will be too much to break (this time around) and could lead to a retrace towards the lower support lines...
I would like to see the final push with possibly a spike above, push the daily RSI into overbought territory, possibly also giving stochs a chance to break above 90 and look to cross downwards. Probably sometime in the next week or so.
Stops above 14300 and possibly just above the upper rising TL...
Worth noting 14282 was the last high and might prove resistance together with the falling resistance line from mid 2008 (in red), if its closer to mid April by that time.

[spaceparallax] 31/3/2011 16:54

Good to see the patents award - interesting to see how the mkt responds tomorrow.

[rivaldo] 31/3/2011 16:24

ATD have a habit of burying good news - first there was the positive trading update, and now this patent news, which could have been embargoed until the morning for maximum effect.

Good to see anyway.

[topinfo] 31/3/2011 15:50

Could this tgt now be increased again?

Asterand and 5AM Solutions team up to develop virtual biobanking software

9:21 am by Sergei Balashov

The companies will share development costs to build software providing a standardized solution for the identification, annotation and distribution of human biological materials for use in research

Asterand (LON:ATD) and 5AM Solutions have entered into a preferred partnership agreement to develop next generation virtual biobanking software for exclusive use by Asterand and its partners.

Asterand and 5AM will electronically link disparate biobanks to Asterand's centralized biobanking operations in Detroit, Michigan.

The companies will share development costs to build software providing a standardized solution for the identification, annotation and distribution of human biological materials for use in research.

The software will enable Asterand to gather biospecimen and data requirements from researchers and query partner biobanks for appropriate specimens.

Once identified, specimens will be selected and qualified for distribution by Asterand.

The goal is to enable broad access to geographically distinct biospecimen resources in an easy to use manner to accelerate discovery in human disease research.

"Our customers require large numbers of highly annotated biological specimens.

We believe that this software will assist us to meet this demand by allowing us to have vision into an ever-increasing network of sophisticated biobanks," said Asterand's vice president of strategic planning and government affairs Victoria Blanc.

Back in January, Daniel Stewart & Company analyst Vadim Alexandre raised his price target on the stock to 30 pence a share from 21 pence, seeing particular value being generated by last year's acquisition of BioSeek.

Alexander said that the group should be valued at a minimum of two times 2011 forecast sales.

The hope is that Asterand is able to build on the progress made during 2010, when it landed a prestigious and valuable five-year contract with America's National Cancer Institute.

Shares in Asterand rose 2.5 percent on the news, reaching 14.75 pence.

[topinfo] 31/3/2011 15:41

DJ Asterand Awarded Key US Patents

LONDON (Dow Jones)--Asterand PLC (ATD.LN), a provider of human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, and its subsidiary BioSeek LLC Thursday announced that the United States Patent and Trademark Office has issued U.S. Patent Nos. 7,908,089 entitled "Patient classification" and 7,912,651 entitled "Function homology screening," adding that the patents cover key methods and applications of the company's BioMAP Systems technology.

MAIN FACTS:

-Patent 7,908,089 relates to BioMAP and its use for the classification of clinical patient tissue specimens according to the physiological status of cells present in the sample.

-Patent 7,912,651 covers key methods of cell selection, culture conditions and screening of biologically active agents utilised by the BioMAP Systems technology.

-Shares at 1435 GMT up 8.06% at GBP0.17 valuing the company at GBP19.42 million.

-By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314; [e-mail]

(END) Dow Jones Newswires

March 31, 2011 10:38 ET (14:38 GMT)

Copyright (c) 2011 Dow Jones & Company, Inc.

[topinfo] 31/3/2011 15:36

Get in there!!!!

DJ Asterand PLC Asterand Awarded Key Patents

TIDMATD

RNS Number : 0493E

Asterand PLC

31 March 2011

For Immediate Release 31 March 2011

ASTERAND PLC

Asterand Awarded Key Patents on the BioMAP Technology

Asterand plc (LSE: ATD), a leading provider of human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, and its subsidiary BioSeek LLC today announced that the United States Patent and Trademark Office has issued U.S. Patent Nos. 7,908,089 entitled "Patient classification" and 7,912,651 entitled "Function homology screening." The patents cover key methods and applications of the company's ground-breaking BioMAP(R) Systems technology.

Patent 7,908,089 relates to BioMAP and its use for the classification of clinical patient tissue specimens according to the physiological status of cells present in the sample. Key embodiments of the invention include the ability to classify patients by assaying their cells in vitro to determine response to therapeutic agents and treatments or the status of activity within pathways of interest. This information may be useful in patient prognosis and diagnosis and can be used to develop surrogate markers for disease states

Patent 7,912,651 covers key methods of cell selection, culture conditions and screening of biologically active agents utilised by the BioMAP Systems technology. Key features of the invention include the identification of complex conditions for simultaneous detection of a large number of cellular pathways and the rapid screening and identification of compounds that cause cellular responses. These methods are useful for the characterisation and prioritisation of drug candidates and compounds based on their impact on human biology. BioSeek scientists are the inventors on both patents, which further strengthens the Company's intellectual property around BioMAP(R) technology.

Martyn Coombs, Chief Executive Officer of Asterand commented:

"Our BioMAP(R) technology represents a truly unique approach and addresses a major unmet need in drug development for model systems that reflect the complexity of human disease. These issued patents represent a key advance as we continue building the intellectual property portfolio around this platform."

BioMAP(R) Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology. Depending on their mechanism of action, drug compounds induce specific patterns of changes in these systems (BioMAP(R) profiles) that can be compared to a large number of reference profiles in the BioMAP(R) Database. BioMAP(R) provides insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.

Contacts:

Asterand plc

Martyn Coombs, Chief Executive Officer Tel: + 44 (0) 1763 211 600 /

+ 1 [phone]

John Stchur, Chief Financial Officer As above

Buchanan Communications

Lisa Baderoon / Mark Court / Isabel Podda Tel: [phone]

Daniel Stewart & Company plc

Antony Legge Tel: [phone]

Martin Lampshire Tel: [phone]

About ASTERAND

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate

[spaceparallax] 31/3/2011 12:14

well done Dan, all helps towards your deposit.

Interestingly, I'm seeing quite a few sells declared albeit outnumbered by buys - one would suspect a very significant background Buy order in play to justify the scale of today's rise.

[danosborne] 31/3/2011 11:52

Suddenly the decision to top up in the slump (with money put aside for other things) seems a little better. Looking at the one day chart it looks like its about to go to 18p.

[rivaldo] 31/3/2011 11:20

Nice - wish I'd topped up with more in my ISA :o((

[danosborne] 31/3/2011 08:39

Yeah looks good. Hopefully the spread will sort itself out though.

[spaceparallax] 31/3/2011 08:32

Looking lively again this morning, albeit with no declared trades so far.

[and then] 30/3/2011 16:18

Anyone who doubts charting....
As an update to the last post, look how it bounced with pin point accuracy off of the earlier falling TL...






A perfect time to cash in the short and go long, even if it was to be the start of the RH shoulder. If the shoulder was already done (albeit short) the indicators screamed 'bounce'!

[and then] 30/3/2011 15:51

Ok, so here was todays play. It doesn't get much better than this! I tried umpteen trades today all of which were unsuccessful :(
This was on the back of me leaving a (small) position open overnight on the EURGBP, (which was dead as a duck yesterday and i didn't consider a problem...
I awoke to find it underwater and becoming more so by the minute... volatility was the name of the game today... Point registered that some days are good scalping days and then there are days like today when the markets are a complete b*stard, cable didn't obey any lines!
Yesterday i became determined to scalp as i hit several good positions and yet failed to take points when they were available through greed.
One point was a breakout from a wedge which had formed through the day, only to see it retrace quite quickly. The points i could have taken were therefore lost and worse, i didn't close the position when the original reason for taking it had failed. All that the spike up out of the existing wedge did, was create another spike point at which to draw a bigger wedge!
Back to today, I found myself stopping out of most trades too early and then, worse, leaving losing trades to run too long, even stopping out of a long trade a mere few points from a bottom.
I noticed the below trade just after 13:00 GMT, typical head and shoulders pattern... I first followed the smaller circled head, entering the trade short with almost perfect timing at 8790. Notice how many things must line up! This is on a 5min chart, but all the indicators were looking to turn down. RSI starting to drop, Stochs dropping and opening, similarly with MACD to follow. Also we had hit overhead resistence, (formed with lines at tops from midnight last night).
My nervousness took me out of the trade on the spike back just over the top of the res line, just after 14:00GMT. As previously learnt though and as mentioned earlier, it only formed a larger head!, so re-entering the trade at the same place... Im expecting some type of RH shoulder to build, possibly off of the earlier falling trendline...

[spaceparallax] 30/3/2011 11:53

Haha, we now have some, albeit a modest volume of trades, revealed. Great to see the share price recovery continuing. Hopefully, we won't be seeing any more major holders shedding significant chunks.

[and then] 30/3/2011 10:22

For reference purposes only






Consolidation on cable short time frames at resistance before the off...

[mansard] 29/3/2011 19:54

ADVN do not show all the trades. There is another 'platform'used. I use Barclaysstockbrokers and after trading in some shares,the deal is often not shown!

[danosborne] 29/3/2011 18:03

Any idea what's going on with the trades not showing today? People are claiming they have brought today but it has not shown up? Anybody here top up today?

[loopeyneuro] 29/3/2011 13:20

Asterand (LON:ATD) and 5AM Solutions have entered into a preferred partnership agreement to develop next generation virtual biobanking software for exclusive use by Asterand and its partners.

Asterand and 5AM will electronically link disparate biobanks to Asterand's centralized biobanking operations in Detroit, Michigan. The companies will share development costs to build software providing a standardized solution for the identification, annotation and distribution of human biological materials for use in research.

The software will enable Asterand to gather biospecimen and data requirements from researchers and query partner biobanks for appropriate specimens. Once identified, specimens will be selected and qualified for distribution by Asterand.

The goal is to enable broad access to geographically distinct biospecimen resources in an easy to use manner to accelerate discovery in human disease research.

"Our customers require large numbers of highly annotated biological specimens. We believe that this software will assist us to meet this demand by allowing us to have vision into an ever-increasing network of sophisticated biobanks," said Asterand's vice president of strategic planning and government affairs Victoria Blanc.

Back in January, Daniel Stewart & Company analyst Vadim Alexandre raised his price target on the stock to 30 pence a share from 21 pence, seeing particular value being generated by last year's acquisition of BioSeek.

Alexander said that the group should be valued at a minimum of two times 2011 forecast sales. The hope is that Asterand is able to build on the progress made during 2010, when it landed a prestigious and valuable five-year contract with America's National Cancer Institute.

Shares in Asterand rose 2.5 percent on the news, reaching 14.75 pence.

[spaceparallax] 29/3/2011 10:32

Good question, I can't really say.

It appears that the MMs are fishing for sellers because I can't yet see any declared trades - must have a substantial buy order to fill.

[oralmex] 29/3/2011 09:44

thanks for those answers, so what is its peer group?

[spaceparallax] 29/3/2011 09:17

This looks like another great collaboration/

btw, I see ATD as neither software or pharmaceutical - I see it as a provider of sophisticated services to the pharmaceutical industry offering them access to the very most appropriate human tissue including access to information already garnered from testing on tissue types.

Hopefully our offloader is nearly done - it's good to see the sp's recovery continue.

[loopeyneuro] 29/3/2011 08:14

Asterand and 5AM Solutions, a life science technology firm, have entered into an agreement to develop next generation virtual biobanking software for exclusive use by Asterand and its collaborators.

[danosborne] 29/3/2011 07:33

It's a pharmaceutical company. The way that I read the RNS is that the new company are going to help asterand to create a database to enable asterands clients to check (and hopefully buy) if the correct product is available to them.

[oralmex] 29/3/2011 07:22

today's RNS - this is what i don't understand about this company, maybe others can enlighten. is this a software company or a pharmaceutical company?

[danosborne] 28/3/2011 20:37

Lets hope so! Would like to see this go up a couple of pence before the 7th!